Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merck Vioxx Sales Will Fall Short Of High Expectations, Firm Says

Executive Summary

Merck's Vioxx sales are showing the impact of a slower penetration rate of COX-2 inhibitors into the analgesic market, the company said June 22.

You may also be interested in...



COX-2 Safety Concerns Are Affecting Celebrex, Pharmacia Says

The withdrawal of Bayer's cholesterol agent Baycol may help Pharmacia in its efforts to differentiate Celebrex from Vioxx in the COX-2 inhibitor class, Global Prescription Business President Carrie Cox suggested during the Bear Stearns "virtual" healthcare conference Sept. 26.

COX-2 Safety Concerns Are Affecting Celebrex, Pharmacia Says

The withdrawal of Bayer's cholesterol agent Baycol may help Pharmacia in its efforts to differentiate Celebrex from Vioxx in the COX-2 inhibitor class, Global Prescription Business President Carrie Cox suggested during the Bear Stearns "virtual" healthcare conference Sept. 26.

Celebrex Growth Is "Typical" Of NSAIDs After Three Years, Pharmacia Says

Pharmacia's Celebrex is showing a growth curve that is typical for products in the non-steroidal anti-inflammatory class, CEO Fred Hassan acknowledged during a July 25 analysts call.

Related Content

UsernamePublicRestriction

Register

PS038080

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel